Last reviewed 2026-04-20 · How we verify

GLPG1205

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Diarrhoea
• Headache
• Asthenia
• Nasopharyngitis
• Dizziness
• Cough
• Fatigue
• Weight decreased
• Abdominal pain
• Dyspnoea
• Decreased appetite

Key clinical trials

• A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) (PHASE2)
• Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205 (PHASE1)
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects (PHASE1)
• This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects (PHASE1)
• A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects (PHASE1)
• Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis (PHASE2)
• Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food (PHASE1)
• First-in-Human Single and Multiple Dose of GLPG1205 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GLPG1205 CI brief — competitive landscape report
• GLPG1205 updates RSS · CI watch RSS
• Galapagos NV portfolio CI